Toms FB ads 9

Cameron Owen

Co-Founder of rBIO

Cameron Owen is the Co-Founder of rBIO, a synthetic biology company that is bringing pharmaceutical supply chains back to the USA by harnessing the power of biology through advances in genetics.

rBIO is currently designing new strains of synthetic microbes to help produce and reduce the cost of insulin in the united states.

Cameron has launched two biotech companies and is looking forward to rewiring the cost structure of essential drugs.

read more
Toms FB ads 9

BOOK NOW FOR your podcast

Cameron Owen

Co-Founder of rBIO

Cameron Owen is the Co-Founder of rBIO, a synthetic biology company that is bringing pharmaceutical supply chains back to the USA by harnessing the power of biology through advances in genetics.

rBIO is currently designing new strains of synthetic microbes to help produce and reduce the cost of insulin in the united states.

Cameron has launched two biotech companies and is looking forward to rewiring the cost structure of essential drugs.

read more

BOOK NOW FOR your podcast

Cameron Owen

Co-Founder of rBIO

Cameron Owen is the Co-Founder of rBIO, a synthetic biology company that is bringing pharmaceutical supply chains back to the USA by harnessing the power of biology through advances in genetics.

rBIO is currently designing new strains of synthetic microbes to help produce and reduce the cost of insulin in the united states.

Cameron has launched two biotech companies and is looking forward to rewiring the cost structure of essential drugs.

read more

As seen on

rBIO, a US-based early-stage synthetic biology company, achieved its first in-lab milestone in December 2020 when it was able to synthetically produce human insulin using its recombinant DNA (rDNA) model and process. The company can achieve upscale production of insulin, potentially lowering the cost of the drug by 30%, as well as identify other prescription drugs that can be manufactured by manipulating microorganisms to express peptide hormones.

read more >

rBIO launched last week with technology that can reduce the cost of insulin by 30 percent, making U.S. manufacturing cost-effective for insulin and several other drugs.

read more >

Ask me

What's the plan for having pharma supply chains here on domestic soil?
What's the importance of having those chains here in USA?
What are you doing differently than everyone else?
What are the results you've seen in the lab?
How has covid affected your business/future plans for business?

Podcast agent: Jon B

jon@kitcaster.com